|Last Price$10.21||Day Change (%)0.29%|
|Open Price$10.26||Day Change ($)0.03|
|Day Range9.87–10.39||52-Week Range5.94–14.28|
As of Fri 03/07/2014 05:05 PM EST | USD
Cytokinetics' CYTK ispinesib trial results for head and neck cancer did not yield a statistically significant change in its patients. We are leaving our fair value estimate at $3.50 per share, as we had already assigned a low probability of success for this indication. Our more conservative ...
Cytokinetics faces challenging odds.